Overview

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

Status:
Completed
Trial end date:
2006-12-12
Target enrollment:
0
Participant gender:
All
Summary
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam
Criteria
Inclusion Criteria:

- Subjects with epilepsy experiencing partial seizures, whether or not secondarily
generalized.

- Subjects must present between 3 and 42 partial seizures over the three months prior to
protocol Visit 1.

- Use of one (1), but no more than two (2) concomitant marketed antiepileptic drugs
(AEDs) at the time of trial entry.

Exclusion Criteria:

- Subjects on vigabatrin, whose visual field has not been assessed as per recommendation
of the manufacturer, i.e. every 6 months.

- Presence of known pseudoseizures within the last year.

- Presence of progressive cerebral disease, any other progressively degenerative
neurological disease, or any cerebral tumors.

- Uncountable seizures (clusters) or history of convulsive status epilepticus within the
last five years.